Literature DB >> 22610755

Interleukin-8 (CXCL8) in tumor associated non-vascular extracellular fluids: its diagnostic and prognostic values. A review.

Jaromír Kotyza1.   

Abstract

Interleukin-8 (IL-8, CXCL8) was originally discovered as a powerful attractor and activator of polymorphonuclear leukocytes. It was soon recognized that IL-8 also affects proliferation and migration of cancer cells, tumor angiogenesis and metastasis, and that it is expressed in many cancerous cell types. IL-8 protein expression is usually increased in serum of cancer patients, but markedly higher concentrations are found in cancer-associated non-vascular extracellular fluids, such as pleural effusion, ascites and cyst fluid. Elevated concentrations of IL-8 are indicative of malignant processes also in cerebrospinal fluid, urine, saliva, interstitial fluid and cervicovaginal secretions. Higher IL-8 levels are typically found in high-grade peritumoral fluids rather than low-grade tumors and benign conditions, with the exception of inflammatory processes. In line with recent molecular biology investigations, it appears that the local IL-8 production is related to its malignant origin and to tumor progression. Hence, IL-8 in peritumoral fluid is to be taken into consideration while assessing tumor character and monitoring the tumor progression/remission status. Besides, the data here collected justify the attempts to find an IL-8-targeted inhibitory therapy

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22610755     DOI: 10.5301/JBM.2012.9261

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  8 in total

1.  Association of serum cytokines with colorectal polyp number and type in adult males.

Authors:  Sarah S Comstock; Diana Xu; Kari Hortos; Bruce Kovan; Sarah McCaskey; Dorothy R Pathak; Jenifer I Fenton
Journal:  Eur J Cancer Prev       Date:  2016-05       Impact factor: 2.497

2.  Continued decline of aqueous interleukin-8 after multiple intravitreal injections of ganciclovir for cytomegalovirus retinitis.

Authors:  Bin Wang; Bei Tian; Yong Tao; Jing Hou; Xiao-Tao Zhao; Xiao-Xin Li
Journal:  J Ocul Pharmacol Ther       Date:  2014-05-29       Impact factor: 2.671

Review 3.  Interleukin-8 in breast cancer progression.

Authors:  Nataša Todorović-Raković; Jelena Milovanović
Journal:  J Interferon Cytokine Res       Date:  2013-05-22       Impact factor: 2.607

4.  Impact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer.

Authors:  Osmond J D'Cruz; Sanjive Qazi; Larn Hwang; Kevin Ng; Vuong Trieu
Journal:  Onco Targets Ther       Date:  2018-05-14       Impact factor: 4.147

5.  Comparison of Cervical Levels of Interleukins-6 and -8 in Patients with and without Cervical Intraepithelial Neoplasia.

Authors:  Zahra Vahedpour; Masoumeh Abedzadeh-Kalahroudi; Mojtaba Sehat; Ahmad Piroozmand; Maedeh Memar
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

6.  Triptolide represses oral cancer cell proliferation, invasion, migration, and angiogenesis in co-inoculation with U937 cells.

Authors:  Cheng-Yu Yang; Chih-Kung Lin; Gu-Jiun Lin; Cheng-Chih Hsieh; Shing-Hwa Huang; Kuo-Hsing Ma; Yi-Shing Shieh; Huey-Kang Sytwu; Yuan-Wu Chen
Journal:  Clin Oral Investig       Date:  2016-04-13       Impact factor: 3.573

7.  IL-8 mediates a positive loop connecting increased neutrophil extracellular traps (NETs) and colorectal cancer liver metastasis.

Authors:  Luyu Yang; Lu Liu; Rui Zhang; Jun Hong; Yaping Wang; Jian Wang; Jieliang Zuo; Jubo Zhang; Jinhong Chen; Hankun Hao
Journal:  J Cancer       Date:  2020-05-18       Impact factor: 4.207

8.  Complement inhibitor factor H expressed by breast cancer cells differentiates CD14+ human monocytes into immunosuppressive macrophages.

Authors:  Karolina I Smolag; Christine M Mueni; Karin Leandersson; Karin Jirström; Catharina Hagerling; Matthias Mörgelin; Paul N Barlow; Myriam Martin; Anna M Blom
Journal:  Oncoimmunology       Date:  2020-03-06       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.